Becton, Dickinson and Company (BDX), commonly known as BD, is a renowned American multinational corporation operating in the global healthcare sector. Founded in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson, BD consistently features among the Fortune 500 corporations. Its headquarters are placed in Franklin Lakes, New Jersey.
BD specializes in manufacturing and marketing a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Its primary target is to enhance the overall quality and accessibility of healthcare, and it operates on a worldwide scale. The firm is structured into three market-focused business segments; BD Medical, BD Life Sciences, and BD Interventional.
BD Medical focuses on improving drug delivery, enhancing the safety and quality of care in clinical settings, and enable home care as well as self-administrated health care. Further, BD Life Sciences offers solutions related to collecting and handling samples, as well as advanced diagnostic tools. Lastly, BD intervention includes surgical and interventional solutions.
As an industry pioneer, BD has marked its footprints on noteworthy innovation in the medical field. For instance, it was the first company to develop a specialized syringe for the delivery of insulin therapy. Additionally, BD created the world’s first multi-sample needle with safety-engineered blood draw systems and lancets.
BD's commitment to sustainability is evident with its focus on conscious and responsible manufacturing and operation processes. BD has received recognition for its efforts on this front; it was listed in the Dow Jones Sustainability World Index and the 100 Most Sustainable Corporations in the world by Corporate Knights.
The company has also made significant strides on the acquisition front. Notably, in 2017, BD acquired C.R. Bard Inc., a leading medical technology company, for a deal amounting to about $24 billion. This was part of its strategy to expand its offering and functioning in the broader healthcare space, particularly in vascular, urology, oncology, and surgical specialty products.
In a nutshell, Becton, Dickinson and Company (BDX) has a significant legacy as a healthcare technology innovator, focusing on the importance of improving both patient outcomes and caregiver safety while integrating sustainability into its core operations.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Dr. Trivikrama Reddy, a Parsippany resident and engineer at BD, has received the inaugural BD Community Excellence Award for his over fifteen years of volunteer service. He was recognized for significant contributions including bringing safe drinking water to an Indian tribal village and promoting STEM education. The award includes a $10,000 charitable grant to a non-profit of his choice.
Becton, Dickinson and Company has appointed Arthur Hu as its new Chief Information and Digital Officer. The announcement was made on September 21, 2026. This leadership change is part of broader management adjustments at the company, which has seen other recent appointments and a retirement.
Two global health firms, West Pharmaceutical Services Inc. and Becton, Dickinson and Co., are planning layoffs in the Phoenix metropolitan area. West Pharmaceutical Services will lay off 98 employees in Scottsdale due to ceasing operations on a product line, while Becton, Dickinson and Co. is moving its manufacturing operations to other facilities.
Apollo Global Management is reportedly in discussions to acquire Johnson & Johnson's DePuy Synthes orthopedics unit for $20 billion, nearly a year after rumors about J&J shedding the unit began. While J&J has confirmed it is exploring options to separate its orthopedics business to maximize value creation, it stated this move is not the start of a broader divestiture program. This potential sale follows J&J's recent spin-off of Kenvue Consumer Health and the sale of its Acclarent portfolio as the company focuses on pharmaceuticals and medical devices.